XSHG
600223
Market cap864mUSD
Oct 09, Last price
5.83CNY
1D
2.46%
1Q
8.36%
Jan 2017
7.17%
IPO
-14.26%
Name
Lushang Property Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lushang Freda Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of cosmetics, pharmaceuticals, raw materials, and additives in China. It is involved in property management services. The company provides facial cleansers, lotions, creams, sprays, masks, and other products. It also offers products in the field of dermatology, orthopedics, ophthalmology, gynecology, and pediatrics, respiratory, endocrinology, andrology, tonic, and plasters, as well as hyaluronic acid and its derivatives, bio-fermentation, plant extracts, chemical synthesis, tablets, capsules, drinks, injections, granules, and other products. The company offers its products through online and offline channels. It exports its products to North America, the European Union, Japan, South Korea, and Southeast Asia. The company was formerly known as Lushang Health Industry Development Co.,Ltd. and changed its name to Lushang Freda Pharmaceutical Co.,Ltd. in April 2023. The company was founded in 1993 and is based in Jinan, China. Lushang Freda Pharmaceutical Co.,Ltd. is a subsidiary of Shandong Commercial Group Co.,Ltd.
Key people
Heng Li
Chief Financial Officer · since 2018
Quanli Zhang
General Manager · since 2019
Wei Yin
Deputy General Manager · since 2019
Hongbo Zhou
Deputy General Manager · since 2019
Lu Li
Secretary of the Board · since 2011
Honglin Dong
Chairman of the Board · since 2019
Qingwen Jia
Director · since 2019
Guangqing Li
Director · since 2009
Xinsheng Li
Director · since 2012
Xi Liang Zhao
Director · since 2013
Independent Director · since 2009
Independent Director · since 2009
Headquarters & legal address
山东省博山经济开发区
淄博市, SD 100000
CN
淄博市, SD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||